This month, Hoosier Cancer Research Network features our member institution Fox Chase Cancer Center, and Daniel M. Geynisman, MD, associate professor, Hematology/Oncology and a medical oncologist at Fox Chase Cancer Center.

Research Interests and Expertise:

Dr. Geynisman’s research interests include genitourinary malignancies, health outcomes, and clinical trial development. As a medical oncologist, he treats patients with adrenal tumors, bladder cancer, kidney cancer, penile cancer, prostate cancer, testicular cancer, ureteral cancer, and urethral cancer. He is board certified in internal medicine and is a member of the American Society of Clinical Oncology. Dr. Geynisman has received numerous awards and honors, including being selected as a participant for ASCO/AACR Methods in Clinical Research Workshop at Vail as well as the Illinois Medical Oncology Society Fellows Award.

Educational Background:

• Medical School: University of Pittsburgh
• Residency and Chief Resident: University of Pittsburgh Medical Center
• Fellowship and Chief Fellow: Hematology and Medical Oncology, University of Chicago
• Fellow: MacLean Center for Clinical Medical Ethics, University of Chicago

Three facts about Dr. Geynisman:

• He was born and raised in St. Petersburg, Russia.
• He loves literary fiction.
• He has three children.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.